Ovarian hyperstimulation syndrome (OHSS) remains a major complication of IVF. Triggering ovulation with human chorionic gonadotrophin (HCG) (as a surrogate to LH) is a major factor in the initiation of OHSS. The pathological process usually intensifies if pregnancy is achieved, as the rising endogenous HCG overstimulates the corpora lutea. Decreasing HCG trigger dose does not prevent OHSS. Gona...

Background GnRH agonist triggering is one of the strategies for ovulation triggering and final maturation of oocytes. So , should be notice for luteal phase support in these cycles. At the first it was began for prevention of severe OHSS but it was associated with luteal phase problem and lower pregnancy rate due to luteolysis effects of GnRH agonists. So, two other alternative strategies have ...

With the increasing use of gonadotropin releasing hormone antagonist protocols, it has become an option to trigger ovulation with gonadotropin releasing hormone agonist which has several advantages over human chorionic gonadotropin triggering; among those an elimination or reduction in ovarian hyperstimulation syndrome, and a reduction in luteal phase discomfort. Thus, this paper questions the ...

OBJECTIVE To review the available knowledge on the use of GnRH agonist for ovulation triggering as a means to prevent ovarian hyperstimulation syndrome (OHSS). DESIGN(S) Review of pertinent English language studies published over the past 15 years. RESULT(S) The available literature suggests that while GnRH agonist effectively induces final oocyte maturation and ovulation, it also completel...

Since the pioneering days of in vitro fertilization, hCG has been the gold standard to induce final follicular maturation. We herein reviewed different pharmaceutical options for triggering of final oocyte maturation in ART. The new upcoming agent seems to be GnRHa with its potential advantages over hCG trigger. GnRHa triggering elicits a surge of gonadotropins resembling the natural midcycle s...

The aim of this study was to investigate whether serum levels of anti-Müllerian hormone (AMH) and inhibin B at ovulation triggering day correlate with the number of immature oocytes obtained from stimulated in vitro fertilization (IVF) cycles. Fifty-nine consecutive cycles of ovarian hyperstimulation and IVF were selected from 45 women who had tubal (n=18) or unexplained infertility (n=27) and ...

Human chorionic gonadotropin (hCG) is no longer a single, omnipotent ovulation triggering option. Gonadotropin releasing hormone (GnRH) agonist, initially presented as a substitute for hCG, has led to a new era of administering GnRH agonist followed by hCG triggering. According to this new concept, GnRH agonist enables successful ovum maturation, while hCG supports the luteal phase and pregnanc...